// App-Quantinova.ai

TPS597 : ALEXANDRA/IMpassion030: A phase 3 study of standard adjuvant chemotherapy with or without atezolizumab in patients with early-stage triple-negative breast cancer.

Researchers

Presenter

  • Shigehira Saji

Principal Investigators

  • Michail Ignatiadis

  • Andrew Bailey

  • Sarra El-Abed

  • Mariana Brandao

  • Otto Metzger

  • Catherine Lai

  • Sebastien Guillaume

  • Debora Fumagalli

  • Dominique Agbor-tarh

  • Aicha Seiller

  • Rosa Altarcheh Xifro

  • Vanessa Honvault

  • Giuseppe Viale

  • Carter DuFrane

  • Teresa Barata

  • Eric P. Winer

  • Richard D. Gelber

  • Martine J. Piccart-Gebhart

Medical Centers

  • Fukushima Medical University School of Medicine, Fukushima, Japan

  • Cedars-Sinai Medical Center, Los Angeles, CA

  • Institute Jules Bordet, Brussels, Belgium

  • Frontier Science, Inverness-shire, United Kingdom

  • Breast International Group, Brussels, Belgium

  • Dana-Farber Cancer Institute, Boston, MA

  • Genentech, Inc., South San Francisico, CA

  • Institute Jules Bordet, Brussels, Belgium

  • Frontier Science (Scotland) Ltd, Kincraig, United Kingdom

  • Roche, Basel, Switzerland.

  • European Institute of Oncology and University of Milan-Bicocca, Milan, Italy

  • Alliance Foundation Trials, Boston, MA

  • Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

  • Dana-Farber Cancer Institute, Harvard Medical School, Harvard TH Chan School of Public Health, and Frontier Science and Technology Research Foundation, Boston, MA

Locations

  • Japan

  • United States

  • Belgium

  • United Kingdom

  • Switzerland

  • Italy

Companies

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Triple-negative breast cancer

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Atezolizumab

  • Doxorubicin

  • Epirubicin

  • Paclitaxel

Outcome

  • N/A

Study Design

  • Randomized

  • Multinational

Phase

  • III

Study Id's

  • NCT03498716

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved